Chengdu Zeling Biomedical Technology Co. Ltd. has described poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment cancer.
Scientists at Jubilant Biosys Ltd. and the University of Texas System have divulged fatty acid binding protein (FABP) inhibitors reported to be useful for the treatment of cancer.
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) and/or (G13D mutant) inhibitors reported to be useful for the treatment of cancer.
Bristol Myers Squibb Co. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases.
Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA-approved T-VEC, have shown safety and some clinical benefit, their limited effectiveness as standalone treatments underscores the need for combination therapies.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is an important factor from a complex downstream of Bruton tyrosine kinase (BTK) in the B-cell receptor (BCR) signaling pathway.
CAR T-cell therapy for B-cell malignancies has still to be improved regarding durability, manufacturing complexity or toxicity, among others. Precigen Inc. has presented data regarding the preclinical development and efficacy of PRGN-3008, a PD-1-expression inhibitor cell therapy targeting CD19 that was built in a next-generation ultra CAR T platform.
Breast cancer is the most frequent malignancy among women worldwide, and all subtypes of breast cancer involve upregulation of the c-Myc gene, making it a compelling therapeutic target. G-rich regions of the c-Myc promoter can form G-quadruplex structures, which can be targeted using small molecules containing a styrylquinolinium core, which then downregulate oncogenic c-Myc. The challenge, however, is specificity.
Researchers at the University of Chicago have shed light on the role of tumor-promoting factors induced by radiotherapy and their potential impact on future therapeutic strategies. The article, published in Nature on May 14, 2025, points to radiation-induced amphiregulin as a key driver of tumor metastasis.
With a PDUFA date less than four weeks away, Urogen Pharma Inc. has been having a rough ride on the Street since the U.S. FDA released a joint briefing document for the May 21 Oncologic Drugs Advisory Committee meeting on UGN-102 (mitomycin).
RSS
